S. Christy Sadreameli, MD, MHS
Johns Hopkins University School of Medicine
Research Project:
Impact of Maryland’s Mandatory Stock Bronchodilator Law on Student Asthma Outcomes
Grant Awarded:
- Public Health and Policy Research Award
Research Topics:
- clinical research
- disparities
- health policy
- implementation science
- public health
Research Disease:
- asthma
Stock bronchodilator laws ensure students with asthma, the most common chronic disease in childhood, have access to life-saving medications during the school day. Typically, the bronchodilator is albuterol, given in inhaler form with a spacer. Though caregivers are currently able to file paperwork and medication with schools for children to receive treatment individually, many families do not complete this process, leaving many children without access to medication during the school day. This can lead to unnecessary suffering, school absenteeism, and avoidable 911 calls. Maryland passed a stock bronchodilator law in 2024. It is the first law in the nation to require public schools to enact the program, rather than making it optional. Though limited published outcomes data show programs are safe and effective, more data about outcomes and effective implementation are needed. We plan to study asthma health outcomes and school absenteeism rates before and after implementation of the law.
Page last updated: October 30, 2025
Your Gift = 2X the Impact
This November, your gift will help fund lifesaving lung disease research—and will be 2X matched, up to $50,000, thanks to a generous family foundation.
